Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 148 is an isotonic crystalloid solution that provides electrolyte replacement and volume expansion. It mimics plasma electrolyte composition, with acetate and gluconate as bicarbonate precursors that are metabolized to bicarbonate in the liver and kidneys, helping to maintain acid-base balance.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Intravenous replacement of extracellular fluid losses,Maintenance of fluid and electrolyte balance,Correction of metabolic acidosis,Off-label: Resuscitation in hypovolemia, perioperative fluid management
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Intravenous infusion; dose determined by electrolyte and fluid requirements. Typical adult rate: 25-100 m L/hour.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Not applicable; Plasma-Lyte 148 contains electrolytes and water that distribute according to body fluid compartments; infusion rate and renal function dictate elimination; clinical context: in normal renal function, excess fluids and electrolytes are cleared with a half-life of approximately 2-4 hours.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Acetate and gluconate are metabolized in the liver and kidneys to bicarbonate. Water and electrolytes are not metabolized but undergo renal excretion.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Renal: >90% of infused electrolytes and water are excreted unchanged in urine. Biliary/fecal excretion is negligible (<1%).
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Not applicable; individual electrolytes do not bind to plasma proteins (e.g., sodium, chloride, potassium, magnesium, acetate, gluconate have negligible protein binding).
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Not applicable as a single value; electrolytes distribute into total body water (approximately 0.6 L/kg in adults); clinical meaning: initial distribution reflects extracellular fluid expansion.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Intravenous: 100% (directly into systemic circulation).
Intravenous: 100%.
No specific dose adjustment; use with caution in renal impairment due to risk of electrolyte imbalances. Monitor serum electrolytes and renal function.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
No specific adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Intravenous infusion; dose based on weight and clinical status. Typical rate: 5-20 m L/kg/hour, adjust based on response.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Use with caution due to potential for fluid overload and electrolyte disturbances; monitor renal function and adjust infusion rate accordingly.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
None
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Risk of fluid overload, especially in patients with heart failure or renal impairment,Electrolyte disturbances (hypernatremia, hyperkalemia, hypokalemia, hypercalcemia, hypermagnesemia) may occur,Monitor serum electrolytes, fluid balance, and renal function,Not recommended for use in patients with severe renal impairment or anuria,Use with caution in patients with metabolic alkalosis or conditions with predisposing factors for electrolyte imbalances
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Hypersensitivity to any component,Severe renal impairment with oliguria or anuria,Hyperkalemia,Metabolic alkalosis,Clinically significant hypercalcemia,Patients with conditions where sodium retention is a concern (e.g., congestive heart failure, edema, cirrhosis)
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
None; PLASMA-LYTE 148 is administered intravenously and does not interact with food. However, patients with electrolyte imbalances may require dietary adjustments (e.g., low potassium or low sodium diet) as directed by their physician.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
No fetal risks have been associated with Plasma-Lyte 148 in Water. It is an isotonic crystalloid solution containing electrolytes and water, lacking known teratogenic properties. No trimester-specific risks reported.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Plasma-Lyte 148 components are endogenous and normally present in breast milk. No specific M/P ratio available; expected to be safe during lactation with usual clinical monitoring.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
Pregnancy may increase total body water and electrolyte requirements; dose adjustments are generally not required but individualize based on maternal status and volume deficits.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
PLASMA-LYTE 148 is a balanced crystalloid solution with physiologic concentrations of electrolytes and p H 7.4. It is preferred over normal saline in patients with hyperchloremic metabolic acidosis or renal impairment. Avoid in patients with severe hyperkalemia, hypercalcemia, or metabolic alkalosis. Do not administer simultaneously with blood products through the same IV line due to risk of hemolysis from calcium content.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This solution is given intravenously to replace fluids and electrolytes.,Report any signs of allergic reaction like rash, itching, or difficulty breathing immediately.,Tell your healthcare provider if you have kidney disease, heart failure, or are on a low-sodium diet.,Inform your doctor if you are pregnant, breastfeeding, or taking any medications.,The infusion site should be monitored for redness, swelling, or pain.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 148 is an isotonic crystalloid solution that provides electrolyte replacement and volume expansion. It mimics plasma electrolyte composition, with acetate and gluconate as bicarbonate precursors that are metabolized to bicarbonate in the liver and kidneys, helping to maintain acid-base balance.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by electrolyte and fluid requirements. Typical adult rate: 25-100 m L/hour.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is classified as Category C. No fetal risks have been associated with Plasma-Lyte 148 in Water. It is an isotonic crystalloid solution containing electrolytes and water, lacking known teratogenic properties. N. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.